Nonalcoholic fatty liver disease (NAFLD), including its more severe manifestation,
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …

Many studies have reported that metabolic dysfunction is closely involved in the complex
mechanism underlying the development of non-alcoholic fatty liver disease (NAFLD), which …

Background & Aims There is substantial inter-individual variability in the risk of non-alcoholic
fatty liver disease (NAFLD). Part of which is explained by insulin resistance (IR)('MetComp') …

The diversity of glycerophospholipid species in cellular membranes is immense and affects
various biological functions. Glycerol-3-phosphate acyltransferases (GPATs) and …

Background Metabolic dysfunction-associated fatty liver disease (MAFLD) is a significant
health issue closely associated with multiple metabolic dysfunctions. The association …

The Lands Pathway is a fundamental biochemical process named for its discovery by
William EM Lands and revealed in a series of seminal papers published in the Journal of …

Das Fortschreiten einer NASH ist assoziiert mit Leberzellstress, konsekutiver Entzündung
und Fibrose, mit potentieller Entwicklung einer Leberzirrhose, portaler Hypertension und der …

Genome‐wide association studies (GWAS) have identified several risk loci for nonalcoholic
fatty liver disease (NAFLD). Previous studies have largely relied on small sample sizes and …

Excess liver fat, called hepatic steatosis, is a leading risk factor for end-stage liver disease
and cardiometabolic diseases but often remains undiagnosed in clinical practice because of …

Nonalcoholic fatty liver disease (NAFLD) is the commonest cause of chronic liver disease
worldwide. It is closely related to obesity, insulin resistance (IR) and dyslipidemia so much …